Literature DB >> 11888903

Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate.

Qing-Bai She1, Nanyue Chen, Ann M Bode, Richard A Flavell, Zigang Dong.   

Abstract

The c-Jun NH(2)-terminal kinase (JNK) has been implicated in regulating cell survival, apoptosis, and transformation. However, the distinct role of JNK isoforms in regulating tumor development is not yet clear. We have found previously that skin tumor formation induced by the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA), is suppressed in JNK2-deficient (Jnk2(-/-)) mice. Here, we show that JNK1-deficient (Jnk1(-/-)) mice are more susceptible to TPA-induced skin tumor development than wild-type mice. The rate of tumor development in Jnk1(-/-) mice was significantly more rapid than that observed in wild-type mice (P < 0.0001). At the end of 33 weeks of TPA promotion, the number of skin tumors and tumors >1.5 mm in diameter per mouse in Jnk1(-/-) mice was significantly increased by 71% (P < 0.03) and 82% (P < 0.03), respectively, relative to the wild-type mice. Furthermore, the carcinoma incidence and the number of carcinomas per mouse were also higher in Jnk1(-/-) mice. Strikingly, Jnk1(-/-) mouse skin was more sensitive to TPA-induced AP-1 DNA binding activity and phosphorylation of extracellular signal-regulated kinases and Akt, which are two important survival signaling components. These results suggest that JNK1 is a crucial suppressor of skin tumor development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888903

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  68 in total

Review 1.  MAPK signaling in inflammation-associated cancer development.

Authors:  Pengyu Huang; Jiahuai Han; Lijian Hui
Journal:  Protein Cell       Date:  2010-02-23       Impact factor: 14.870

2.  Loss of JNK2 increases intestinal tumor susceptibility in Apc1638+/- mice with dietary modulation.

Authors:  Xiuli Bi; Nicole M Pohl; Zhinan Yin; Wancai Yang
Journal:  Carcinogenesis       Date:  2010-12-23       Impact factor: 4.944

3.  Non-cell-autonomous induction of tissue overgrowth by JNK/Ras cooperation in a Drosophila tumor model.

Authors:  Mirka Uhlirova; Heinrich Jasper; Dirk Bohmann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

4.  Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation.

Authors:  Cristina Cellurale; Guadalupe Sabio; Norman J Kennedy; Madhumita Das; Marissa Barlow; Peter Sandy; Tyler Jacks; Roger J Davis
Journal:  Mol Cell Biol       Date:  2011-01-31       Impact factor: 4.272

5.  Requirements for PKC-augmented JNK activation by MKK4/7.

Authors:  Pablo Lopez-Bergami; Ze'ev Ronai
Journal:  Int J Biochem Cell Biol       Date:  2007-12-03       Impact factor: 5.085

Review 6.  Targeting innate immunity protein kinase signalling in inflammation.

Authors:  Matthias Gaestel; Alexey Kotlyarov; Michael Kracht
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

7.  c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis.

Authors:  Jing Liu; Yuzuru Minemoto; Anning Lin
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

8.  c-Jun N-terminal kinase 1 interacts with and negatively regulates Wnt/beta-catenin signaling through GSK3beta pathway.

Authors:  Dong Hu; Wenfeng Fang; Anjia Han; Lindsay Gallagher; Roger J Davis; Bin Xiong; Wancai Yang
Journal:  Carcinogenesis       Date:  2008-10-24       Impact factor: 4.944

9.  The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer.

Authors:  Jennifer Y Zhang; Maria Angelica Selim
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

10.  c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.

Authors:  X Xie; T S Kaoud; R Edupuganti; T Zhang; T Kogawa; Y Zhao; G B Chauhan; D N Giannoukos; Y Qi; D Tripathy; J Wang; N S Gray; K N Dalby; C Bartholomeusz; N T Ueno
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.